Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RLX-2508
- Development stage
- Phase 1
- Lead developer
- Guangdong Hengrui Pharmaceutical
- Administration
- Parenteral
01
Overview
RLX-2508 is an investigational therapeutic biologic being developed for the treatment of influenza. Originally developed by Suzhou Renolynx Therapeutics (also known as Suzhou Tuojie Pharmaceutical) and subsequently co-developed with Guangdong Hengrui Pharmaceutical, RLX-2508 is currently in Phase 1 clinical development. The specific biological target and molecular mechanism of action of RLX-2508 have not been publicly disclosed, but it is formulated as an injection and is being evaluated for safety, tolerability, pharmacokinetics, and immunogenicity in healthy adult participants.
- Other names
- RLX-2508 injectionRLX2508 injectionRLX 2508 injectionRLX-2508注射液RLX2508RLX-2508RLX 2508
Beyond the preview
Go deeper on RLX-2508.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RLX-2508.